Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Gilead Sciences Inc(GILD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low142.77
Day High144.65
Open:143.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Gilead Sciences Inc

Select a category then submit the form to load news
Motley Fool
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing
Newswire.ca
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Motley Fool
Compugen (CGEN) Q4 2025 Earnings Call Transcript
Motley Fool
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement
Motley Fool
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement
Motley Fool
Kymera (KYMR) Q4 2025 Earnings Call Transcript
Motley Fool
Arcus (RCUS) Q4 2025 Earnings Call Transcript
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Oric Pharmaceuticals (ORIC), Option Care Health (OPCH)
Tipranks
Gilead Sciences (GILD) Receives a Buy from Scotiabank
Tipranks
Citi Reaffirms Their Buy Rating on Gilead Sciences (GILD)
StockStory
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
NFLX
Newswire.ca
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
Tipranks
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Gilead Sciences (GILD)
Tipranks
Gilead Sciences to Acquire Arcellx in Major Cell-Therapy Deal
Motley Fool
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Newswire.ca
Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
StockStory
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call
GILD
StockStory
3 Hyped Up Stocks We Steer Clear Of
SITE
StockStory
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
COR
Zacks Investment Research
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
StockStory
3 Overrated Stocks That Concern Us
VSH
Tipranks
Gilead Sciences Earnings Call: HIV Strength, New Catalysts
Tipranks
Scotiabank Keeps Their Buy Rating on Gilead Sciences (GILD)
Tipranks
Gilead Sciences (GILD) Gets a Buy from J.P. Morgan
Tipranks
RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)
StockStory
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook
GILD
Motley Fool
Gilead (GILD) Q4 2025 Earnings Call Transcript
StockStory
Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates
GILD
ValuEngine, Inc
02/09/2026 ValuEngine Weekly Market Summary & Commentary
Zacks Investment Research
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Motley Fool
Should You Buy Gilead Sciences Before Feb. 10?

Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.